It was also reported that majority of the physicians agreed with the continuation of AFP until recovery from neutropenia and CR for AML/MDS patients (74.2%) and throughout the immunosuppressive period for GvHD patients after allogeneic HSCT (80.6%). This evidence concerns the gene AFP and acute myeloid leukemia.